* Sellas Life Sciences Group Inc SLS.OQ reported a
quarterly
adjusted loss of 25 cents per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of -43 cents. The mean expectation of
four analysts for the quarter was for breakeven results per
share. Wall Street expected results to range from -27 cents
to 12 cents per share.
* Reported revenue was zero; analysts expected $13.00
million.
* Sellas Life Sciences Group Inc's reported EPS for the
quarter
was a loss of 25 cents.
* The company reported a quarterly loss of $8.14 million.
* Sellas Life Sciences Group Inc shares had fallen by 2.8%
this
quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 103.2% in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Sellas Life
Sciences Group Inc is $7.50
This summary was machine generated from LSEG data March 28 at
09:46 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 0.00 -0.25 Missed
Sep. 30 2023 0.03 -0.33 Missed
Jun. 30 2023 -0.35 -0.31 Beat
Mar. 31 2023 -0.29 -0.47 Missed